Savolitinib is a Small Molecule owned by Hutchison MediPharma, and is involved in 36 clinical trials, of which 18 were completed, 14 are ongoing, and 4 are planned.

Savolitinib (AZD-6094) acts as selective c-Met inhibitor. The c-Met signalling pathway has specific roles particularly in normal mammalian growth and development, and this pathway function abnormally in a range of different cancers. c-Met signaling is implicated in a wide variety of human malignancies. The c-Met pathway activates a program of cell dissociation and motility coupled with increased protease production that has been shown to promote cellular invasion through extracellular matrices and that closely resembles tumor metastasis. The drug candidate, by antagonizing c-Met receptor, elicits the therapeutic intervention.

The revenue for Savolitinib is expected to reach a total of $2.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Savolitinib NPV Report.

Savolitinib is originated and owned by Hutchison MediPharma. AstraZeneca and Hutchmed China are the other companies associated in development or marketing of Savolitinib.

Savolitinib Overview

Savolitinib (Orpathys) is a potent antineoplastic agent. It is formulated as tablets for the oral route of administration. Orpathys is indicated for the treatment of patients with non-small cell lung cancer who have progressed following prior systemic therapy or are unable to receive chemotherapy.

Savolitinib (AZD-6094) is under development for the treatment of gastric cancer, adenocarcinoma of the gastroesophageal junction, papillary, metastatic castration-resistant prostate cancer, non-small cell lung cancer, advanced or metastatic pulmonary sarcomatoid carcinoma, metastatic colorectal cancer. The drug candidate is administered orally. Volitinib acts by targeting ATP-competitive c-Met receptor.

It was also under development for primary CNS tumors including medulloblastoma, high-grade glioma and diffuse intrinsic pontine glioma, solid tumors, clear cell renal cell carcinoma, breast cancer and hepatocellular carcinoma

AstraZeneca Overview

AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

The company reported revenues of (US Dollars) US$37,417 million for the fiscal year ended December 2021 (FY2021), an increase of 40.6% over FY2020. In FY2021, the company’s operating margin was 2.8%, compared to an operating margin of 19.4% in FY2020. In FY2021, the company recorded a net margin of 0.3%, compared to a net margin of 12% in FY2020. The company reported revenues of US$10,982 million for the third quarter ended September 2022, an increase of 2% over the previous quarter.

Quick View – Savolitinib

Report Segments
  • Innovator (NME)
Drug Name
  • Savolitinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.